Shandong Wohua Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002107.SZ

Shandong Wohua Pharmaceutical Co., Ltd. EBIT for the year ending December 31, 2023: USD 7.71 M

Shandong Wohua Pharmaceutical Co., Ltd. EBIT is USD 7.71 M for the year ending December 31, 2023, a -51.96% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Shandong Wohua Pharmaceutical Co., Ltd. EBIT for the year ending December 31, 2022 was USD 16.06 M, a -47.92% change year over year.
Shandong Wohua Pharmaceutical Co., Ltd. EBIT for the year ending December 31, 2021 was USD 30.83 M, a -11.11% change year over year.
Shandong Wohua Pharmaceutical Co., Ltd. EBIT for the year ending December 31, 2020 was USD 34.69 M, a 111.07% change year over year.
Shandong Wohua Pharmaceutical Co., Ltd. EBIT for the year ending December 31, 2019 was USD 16.43 M, a 125.62% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Shenzhen Stock Exchange: 002107.SZ

Shandong Wohua Pharmaceutical Co., Ltd.

CEO	Ms. Yingzi Zeng
IPO Date	Jan. 24, 2007
Location	China
Headquarters	No. 3517 Liyuan Street
Employees	1,353
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Shandong Wohua Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in China. It offers Xinkeshu tablets, Naoxueshu oral solutions, Tongluo Huayu capsules, and oral liquids for cardiovascular and cerebrovascular; respiratory system drugs; medicines for women and children; urinary system drugs; digestive system drugs; anti-rheumatic drugs; and drugs for soothe the nerves. The company is based in Weifang, China. Shandong Wohua Pharmaceutical Co., Ltd. is a subsidiary of Beijing Zhongzheng Wanrong Investment(Group) Co., Ltd.

Key trends

Past 5 years